Physician profile
Mae Tighe
NPI 1184765844
$39,130.43
in general payments reported to CMS, 2019-2025
11 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,910 · 2020: $4,270 · 2021: $8,432 · 2022: $7,679 · 2023: $9,193 · 2024: $414 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,625 · Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,625.00 |
| Food and Beverage | $1,213.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37,229.30 | 2019-2023 | Trulance, Xifaxan |
| Abbvie INC. | $821.03 | 2019-2025 | Skyrizi, Rinvoq |
| Allergan, INC. | $400.00 | 2019 | |
| Genzyme Corporation | $154.53 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2019 | |
| Pfizer INC. | $122.92 | 2019 | |
| Madrigal Pharmaceuticals | $116.77 | 2024 | Rezdiffra |
| Boston Scientific Corporation | $104.20 | 2019-2020 | |
| Celgene Corporation | $30.11 | 2022 | |
| Ardelyx, INC. | $26.57 | 2025 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mae Tighe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.